The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Jeremy Pearlman - Maxim Group - Analyst
: Good morning. Yeah, thank you for taking my question. Just quickly on the Veris Health Care Cancer platform with the Ohio State pilot program.
So it seems like it was extended through April. It seems like the finalizing the contract. I mean, what is -- based on your conversations you're having
with them, what does that contract do you think look like? How is it going to play out.
Question: Jeremy Pearlman - Maxim Group - Analyst
: Understood, thank you. And then just one follow-up question. You mentioned the implantable device. Now that you have funding for that. Do you
have any more clarity how that time line would look until you hopefully get potential FDA approval for that?
Question: Jeremy Pearlman - Maxim Group - Analyst
: Okay, great. Thank you for that information, and I'll hop back in the queue.
Question: Matthew Park - Cantor Fitzgerald - Analyst
: Hey guys, this is Matthew Park on for Ross today. Thanks for taking my questions. I guess just one for me. Can you give us some color on the
discussions you're having with other institutions on Veris to initiate pilot launches and any learnings you can take from what you're doing at OSU,
when going into other centers?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MARCH 25, 2025 / 12:30PM, PAVM.OQ - Q4 2024 PAVmed Inc Earnings Call
Question: Matthew Park - Cantor Fitzgerald - Analyst
: Got it. Super helpful makes sense. And then I guess one more for me on PortIO. So pending any incremental financing, can you just walk us through
what the path to FDA approval would look like here? And any additional studies you need to go through?
Question: Matthew Park - Cantor Fitzgerald - Analyst
: Got it. That makes sense. Thanks for taking the questions guys.
Question: Ed Woo - Ascendiant Capital - Analyst
: Yeah, congratulations on all the progress. My question is on Veris. As you're possibly talking to other cancer centers, have you run into any competing
products or competition out there?
Question: Ed Woo - Ascendiant Capital - Analyst
: Great. Well, thanks for answering my questions. I wish you guys good luck. Thank you.
| 
